SPECT/CT-based dosimetry of salivary glands and iodine-avid lesions following 131I therapy.

IF 3.1 Q2 MEDICAL INFORMATICS Health and Technology Pub Date : 2023-01-01 DOI:10.1007/s12553-022-00718-y
Mohammad Abuqbeitah, Mustafa Demir, Sağit Sağer, Sertaç Asa, Nazenin Ipek Işıkcı, Kerim Sönmezoğlu
{"title":"SPECT/CT-based dosimetry of salivary glands and iodine-avid lesions following <sup>131</sup>I therapy.","authors":"Mohammad Abuqbeitah,&nbsp;Mustafa Demir,&nbsp;Sağit Sağer,&nbsp;Sertaç Asa,&nbsp;Nazenin Ipek Işıkcı,&nbsp;Kerim Sönmezoğlu","doi":"10.1007/s12553-022-00718-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The purpose was to provide uptake and radiation dose estimates to salivary glands (SG) and pathologic lesions following radioiodine therapy (RIT) of differentiated thyroid cancer patients (DTC).</p><p><strong>Methods: </strong>A group of DTC patients (n = 25) undergoing <sup>131</sup>I therapy joined this study with varying amounts of therapeutic activity. Sequential SPECT/CT scans were acquired at 4 ± 2, 24 ± 2, and 168 ± 3 h following administration of 3497-9250 MBq 131I. An earlier experiment with Acrylic glass body phantom (PET Phantom NEMA 2012 / IEC 2008) was conducted for system calibration including scatter, partial volume effect and count loss correction. Dose calculation was made via IDAC-Dose 2.1 code.</p><p><strong>Results: </strong>The absorbed dose to parotid glands was 0.04-0.97 Gy/GBq (median: 0.26 Gy/GBq). The median absorbed dose to submandibular glands was 0.14 Gy/GBq (0.05 to 0.56 Gy/GBq). The absorbed dose to thyroid residues was from 0.55 to 399.5 Gy/GBq (median: 21.8 Gy/GBq), and that to distal lesions ranged from 0.78 to 28.0 Gy/GBq (median: 3.12 Gy/GBq). 41% of the thyroid residues received dose > 80 Gy, 18% between 70-80 Gy, 18% between 40-70 Gy, and 23% has dose < 40 Gy. In contrast, 18% of the metastases exhibited a dose > 80 Gy, 9% between 40-60 Gy, and the dose to the vast majority of lesions (64%) was < 40 Gy.</p><p><strong>Conclusion: </strong>It was inferred that dose estimation after RIT with SPECT/CT is feasible to apply, together with good agreement with published <sup>124</sup>I PET/CT dose estimates. A broad and sub-effective dose range was estimated for thyroid residues and distal lesions. Moreover, the current methodology might be useful for establishing a dose-effect relationship and radiation-induced salivary glands damage after RIT.</p>","PeriodicalId":12941,"journal":{"name":"Health and Technology","volume":"13 1","pages":"101-110"},"PeriodicalIF":3.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817440/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12553-022-00718-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL INFORMATICS","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The purpose was to provide uptake and radiation dose estimates to salivary glands (SG) and pathologic lesions following radioiodine therapy (RIT) of differentiated thyroid cancer patients (DTC).

Methods: A group of DTC patients (n = 25) undergoing 131I therapy joined this study with varying amounts of therapeutic activity. Sequential SPECT/CT scans were acquired at 4 ± 2, 24 ± 2, and 168 ± 3 h following administration of 3497-9250 MBq 131I. An earlier experiment with Acrylic glass body phantom (PET Phantom NEMA 2012 / IEC 2008) was conducted for system calibration including scatter, partial volume effect and count loss correction. Dose calculation was made via IDAC-Dose 2.1 code.

Results: The absorbed dose to parotid glands was 0.04-0.97 Gy/GBq (median: 0.26 Gy/GBq). The median absorbed dose to submandibular glands was 0.14 Gy/GBq (0.05 to 0.56 Gy/GBq). The absorbed dose to thyroid residues was from 0.55 to 399.5 Gy/GBq (median: 21.8 Gy/GBq), and that to distal lesions ranged from 0.78 to 28.0 Gy/GBq (median: 3.12 Gy/GBq). 41% of the thyroid residues received dose > 80 Gy, 18% between 70-80 Gy, 18% between 40-70 Gy, and 23% has dose < 40 Gy. In contrast, 18% of the metastases exhibited a dose > 80 Gy, 9% between 40-60 Gy, and the dose to the vast majority of lesions (64%) was < 40 Gy.

Conclusion: It was inferred that dose estimation after RIT with SPECT/CT is feasible to apply, together with good agreement with published 124I PET/CT dose estimates. A broad and sub-effective dose range was estimated for thyroid residues and distal lesions. Moreover, the current methodology might be useful for establishing a dose-effect relationship and radiation-induced salivary glands damage after RIT.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于SPECT/ ct的131I治疗后唾液腺和碘中毒病变剂量测定。
目的:为分化型甲状腺癌(DTC)患者放射碘治疗(RIT)后唾液腺(SG)和病理病变的吸收和辐射剂量提供估计。方法:一组接受131I治疗的DTC患者(n = 25)以不同的治疗活性加入本研究。在给药3497-9250 MBq 131I后4±2、24±2和168±3小时进行顺序SPECT/CT扫描。前期实验采用丙烯酸玻璃体模体(PET phantom NEMA 2012 / IEC 2008)进行系统标定,包括散射、部分体积效应和计数损耗校正。剂量计算采用IDAC-Dose 2.1程序。结果:腮腺吸收剂量为0.04 ~ 0.97 Gy/GBq(中位数:0.26 Gy/GBq)。颌下腺的中位吸收剂量为0.14 Gy/GBq (0.05 ~ 0.56 Gy/GBq)。甲状腺残留吸收剂量范围为0.55 ~ 399.5 Gy/GBq(中位数:21.8 Gy/GBq),远端病变吸收剂量范围为0.78 ~ 28.0 Gy/GBq(中位数:3.12 Gy/GBq)。41%的甲状腺残留物接受剂量> 80 Gy, 18%在70-80 Gy之间,18%在40-70 Gy之间,23%的剂量为80 Gy, 9%在40-60 Gy之间,绝大多数病变(64%)的剂量为。结论:推断SPECT/CT RIT后的剂量估计是可行的,并且与已发表的124I PET/CT剂量估计吻合良好。估计甲状腺残留和远端病变的剂量范围很广,而且亚有效。此外,目前的方法可能有助于建立RIT后剂量效应关系和辐射引起的唾液腺损伤。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Health and Technology
Health and Technology MEDICAL INFORMATICS-
CiteScore
7.10
自引率
0.00%
发文量
83
期刊介绍: Health and Technology is the first truly cross-disciplinary journal on issues related to health technologies addressing all professions relating to health, care and health technology.The journal constitutes an information platform connecting medical technology and informatics with the needs of care, health care professionals and patients. Thus, medical physicists and biomedical/clinical engineers are encouraged to write articles not only for their colleagues, but directed to all other groups of readers as well, and vice versa.By its nature, the journal presents and discusses hot subjects including but not limited to patient safety, patient empowerment, disease surveillance and management, e-health and issues concerning data security, privacy, reliability and management, data mining and knowledge exchange as well as health prevention. The journal also addresses the medical, financial, social, educational and safety aspects of health technologies as well as health technology assessment and management, including issues such security, efficacy, cost in comparison to the benefit, as well as social, legal and ethical implications.This journal is a communicative source for the health work force (physicians, nurses, medical physicists, clinical engineers, biomedical engineers, hospital engineers, etc.), the ministries of health, hospital management, self-employed doctors, health care providers and regulatory agencies, the medical technology industry, patients'' associations, universities (biomedical and clinical engineering, medical physics, medical informatics, biology, medicine and public health as well as health economics programs), research institutes and professional, scientific and technical organizations.Health and Technology is jointly published by Springer and the IUPESM (International Union for Physical and Engineering Sciences in Medicine) in cooperation with the World Health Organization.
期刊最新文献
Health disparity in digital health technology design Training protocol for driving power wheelchairs using virtual environment: preliminary results from a pilot study COVID-19 vaccine prediction based on an interpretable CNN-LSTM model with three-stage feature engineering Detection of Cardio Vascular abnormalities using gradient descent optimization and CNN Unsupervised machine learning for disease prediction: a comparative performance analysis using multiple datasets
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1